Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MAPK13 | O15264 | 3/20 | 0.40 |
| ▸ | MAPK12 | P53778 | 3/20 | 0.40 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.40 |
| ▸ | IGFBP3 | P17936 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | RORB | Q92753 | 2/20 | 0.38 |
| ▸ | RORC | P51449 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4016377 | 0.75 | LMNA (0.37) | RECQLALDH1A1LMNAGAATP53 | |
| SCHEMBL4015280 | 0.75 | LMNA (0.37) | RECQLALDH1A1LMNAGAATP53 | |
| SCHEMBL4019203 | 0.75 | NPC1 (0.37) | RECQLALDH1A1LMNAGAATP53 | |
| SCHEMBL4019207 | 0.75 | NPC1 (0.37) | RECQLALDH1A1LMNAGAATP53 | |
| SCHEMBL2189708 | 0.71 | ALDH1A1 (0.57) | RECQLCES2CES1ALDH1A1GAA | |
| SCHEMBL29399311 | 0.70 | CES2 (0.71) | RECQLCES2CES1ALDH1A1LMNA | |
| SCHEMBL50416 | 0.70 | CES2 (0.71) | RECQLCES2CES1ALDH1A1LMNA | |
| SCHEMBL8956220 | 0.69 | RECQL (0.51) | RECQLCES2CES1ALDH1A1LMNA | |
| SCHEMBL611462 | 0.68 | MEN1 (0.54) | CES2CES1ALDH1A1LMNAGAA | |
| SCHEMBL3444846 | 0.68 | CES2 (0.68) | RECQLCES2CES1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7566708-B2 | Substituted pyrazolo{3,4-D}pyrimidines as p38 map kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2009-07-28 | — | — | US | disclosed |
| US-7566708-B2 | Substituted pyrazolo{3,4-D}pyrimidines as p38 map kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2009-07-28 | — | — | US | disclosed |
| US-7566708-B2 | Substituted pyrazolo{3,4-D}pyrimidines as p38 map kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2009-07-28 | — | — | US | disclosed |
| US-7435731-B2 | Substituted pyrazolo[3,4-d]pyrimadines and methods of using the same | ROCHE PALO ALTO LLC (US) | 2008-10-14 | — | — | US | disclosed |
| US-7435731-B2 | Substituted pyrazolo[3,4-d]pyrimadines and methods of using the same | ROCHE PALO ALTO LLC (US) | 2008-10-14 | — | — | US | disclosed |
| US-7435731-B2 | Substituted pyrazolo[3,4-d]pyrimadines and methods of using the same | ROCHE PALO ALTO LLC (US) | 2008-10-14 | — | — | US | disclosed |
| EP-1919470-A1 | FUSED PYRAZOLE AS p38 MAP KINASE INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-05-14 | — | — | EP | disclosed |
| US-20070203160-A1 | p38 MAP kinase inhibitors and methods for using the same | ROCHE PALO ALTO LLC | 2007-08-30 | — | — | US | disclosed |
| US-20070203160-A1 | p38 MAP kinase inhibitors and methods for using the same | ROCHE PALO ALTO LLC | 2007-08-30 | — | — | US | disclosed |
| US-20070203160-A1 | p38 MAP kinase inhibitors and methods for using the same | ROCHE PALO ALTO LLC | 2007-08-30 | — | — | US | disclosed |
| WO-2007023105-A1 | FUSED PYRAZOLE AS p38 MAP KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-03-01 | — | — | WO | disclosed |
| EP-1737865-A1 | FUSED DERIVATIVES OF PYRAZOLE | F.HOFFMANN-LA ROCHE AG (CH) | 2007-01-03 | — | — | EP | disclosed |
| WO-2005085249-A1 | FUSED DERIVATIVES OF PYRAZOLE | F. HOFFMANN-LA ROCHE AG (CH) | 2005-09-15 | — | — | WO | disclosed |
| US-20050197340-A1 | Fused-pyrazolo pyrimidine and pyrazolo pyrimidinone derivatives and methods for using the same | ROCHE PALO ALTO LLC | 2005-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197340-A1 | Fused-pyrazolo pyrimidine and pyrazolo pyrimidinone derivatives and methods for using the same | MAP3K1, MAPK1, MAP3K8 | RECQL 803/4885CES2 4429/4885CES1 3049/4885 |
| US-20070203160-A1 | p38 MAP kinase inhibitors and methods for using the same | MAPKAPK2, MAPK1, MAP3K2 | RECQL 3803/4885CES2 3229/4885CES1 2303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.